Comprehensive treatment of squamous cell cancer of head and neck: Chinese expert consensus 2013

Future Oncology

Volumn 10, Issue 9, 2014, Pages 1635-1648

  Lang, Jinyi ^a   Gao, Li ^b   Guo, Ye ^c   Zhao, Chong ^d   Zhang, Chenping ^e  

^a SICHUAN CANCER HOSPITAL   (China)

^b CANCER HOSPITAL   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

expert consensus; head and neck cancer; multidisciplinary treatment; nasopharyngeal cancer; squamous cell cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHINESE; CLINICAL PRACTICE; CONSENSUS; EARLY CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH RISK PATIENT; HUMAN; HYPOPHARYNX CANCER; MEDICAL SPECIALIST; MOUTH CANCER; NASOPHARYNX CANCER; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; CARCINOMA, SQUAMOUS CELL; CHINA; CONSENSUS DEVELOPMENT; COOPERATION; DISEASE MANAGEMENT; HEAD AND NECK NEOPLASMS; INDUCTION CHEMOTHERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; SALVAGE THERAPY; SECONDARY;

CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CHINA; COOPERATIVE BEHAVIOR; DISEASE MANAGEMENT; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY;

EID: 84906568647     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.44     Document Type: Article

References (77)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005
2. Ferlay F, Bray F, Pisani P, Parkin DM. Globocan 2002: Cancer Incidence, Mortality and Prevalence Worldwide. Iarc Cancer Base No. 5, Version 2.0. International Agency for Research on Cancer, Lyon, France (2004
3. Bozec A, Peyrade F, Fischel JL, Milano G. Emerging molecular targeted therapies in the treatment of head and neck cancer. Expert Opin Emerg. Drugs 14, 299-310 (2009
4. NCCN Clinical Practice Guidelines in Oncology. Head and neck cancer. v1, 2012.www.nccn.org/professionals/physician-gls/f-guidelines.asp
5. The 2012 Chinese Cancer Registry Annual Report. Military Science and Technology Press, Beijing, China (2012
6. Gillison ML, Koch WM, Capone RB et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl Cancer Inst. 92, 709-720 (2000
7. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and-unrelated oral squamous cell carcinomas in the United States. J. Clin. Oncol. 26, 612-619 (2008
8. Näsman A, Attner P, Hammarstedt L et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int. J. Cancer 125, 362-366 (2009
9. Hammarstedt L, Lindquist D, Dahlstrand H et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int. J. Cancer 119, 2620-2623 (2006
10. Parkin DM, Whelan SL, Ferlay J et al. Cancer Incidence in Five Continents, vol. VIii. IARC Scientific Publication No. 155. International Agency for Research on Cancer, Lyon, France (2002
11. Liu Z, Li B, Liu Y et al. Study on the synergy effect of EB virus and tumor promoters in inducing human nasopharyngeal malignant lymphoma and undifferentiated cancer. Chin. J. Virol. 12, 1-8 (1996
12. Feng H, Huang G. Development of Epstein-Barr virus on progression of nasopharyngeal carcinoma. Chin. J. Cancer Pretreat. 15, 1753-1755 (2008
13. Edge SB, Byrd DR, Compton CC et al. AJCC Cancer Staging Manual (7th Edition). Springer, NY, USA (2010
14. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a Phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11, 21-28 (2010
15. Lefebvre JL, Pointreau Y, Rolland F et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized Phase II study. J. Clin. Oncol. 31(7), 853-859 (2013
16. Parthan A, Posner MR, Brammer C et al. Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck. Head Neck 31, 1255-1262 (2009
17. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359, 1116-1127 (2008
18. Chen C, Zhao C, Gao L et al. An open-labeled, multicentric clinical study of cetuximab combined with intensity-modulated radiotherapy (IMRT) plus concurrent chemotherapy in locoregionally advanced (LA) nasopharyngeal carcinoma (NPC): a 2-year follow-up report. J. Clin. Oncol. 30(Suppl.), Abstract 5535 (2012
19. Comprehensive treatment of squamous cell cancer of head and neck (SCCHN): expert consensus. Chin. J. Otorhinolaryngol. Head Neck Surg. 45, 535-541 (2010
20. Grégoire V, Lefebvre JL, Licitra L, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), v184-v186 (2010
21. Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on, randomised trials and 17,346 patients. Radiother. Oncol. 92, 4-14 (2009
22. Bernier J, Cooper JS, Pajak TF et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27, 843-850 (2005
23. Machtay M, Moughan J, Trotti A et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J. Clin. Oncol. 26, 3582-3589 (2008
24. Argiris A, Brockstein BE, Haraf DJ et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin. Cancer Res. 10, 1956-1962 (2004
25. Bemier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 350, 1945-1952 (2004
26. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94, 1593-1611 (2002
27. Ghi MG, Paccagnella A, Ferrari D et al. A Phase II-Iii study comparing concomitant chemoradiotherapy (CRT) versus cetuximab/RT (CET/RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): efficacy results (NCT01086826). J. Clin. Oncol. 31(15 Suppl.), Abstract 6003 (2013
28. Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med. 357, 1695-1704 (2007
29. Vermorken JB, Remenar E, van Herpen C et al. Long-term results from EORTC24971/TAX323: comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol(15 Suppl.), Abstract 5530 (2011
30. Pointreau Y, Garaud P, Chapet S et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J. Natl Cancer Inst. 101, 498-506 (2009
31. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med. 357, 1705-1715 (2007
32. Hitt R, López-Pousa A, Martínez-Trufero J et al. Phase Iii study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol. 23, 8636-8645 (2005
33. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 350, 1937-1944 (2004
34. Cooper JS, Zhang Q, Pajak TF et al. Long-term follow-up of the RTOG 9501/intergroup Phase Iii trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int. J. Radiat. Biol. Phys. 84, 1198-1205 (2012
35. Zhang Z, Tang P, Xu Z et al. Significance of different preoperative radiotherapy doses in combined therapy for hypopharyngeal squamous cell carcinoma. Chin. J. Radiat. Oncol. 13, 1-3 (2004
36. Wang X, Xu Z, Tang P. Surgical treatment on primary lesion of advanced pyriform sinus cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 28, 534-537 (2006
37. Wang X, Xu Z, Tang P. Comprehensive treatment of advanced pyriform sinus cancer. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 41, 123-127 (2006
38. Beitler JJ, Zhang Q, Fu KK et al. RTOG 90-03: final report. Int. J. Radiat. Biol. Phys. 84(Suppl. 1), S6 (2012
39. Ang K, Zhang Q, Wheeler RH et al. A Phase Iii trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): impact of radiation and cisplatin intensity on outcome. J. Clin. Oncol. 28(15 Suppl.), Abstract 5507 (2010
40. Jacobs C, Lyman G, Velez-García E et al. A Phase Iii randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. 10, 257-263 (1992
41. Gibson MK, Li Y, Murphy B et al. Randomized Phase Iii evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 23, 3562-3567 (2005
42. Guigay J, Fayette J, Dillies AF et al. Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): final results of Phase II trial GORTEC 2008-2003. J. Clin. Oncol. 30(Suppl.), Abstract 5505 (2012
43. Rozzi A, Lenci G, Nardoni C et al. Weekly regimen of paclitaxel- carboplatin-cetuximab as first-line chemotherapy in patients with platinum-resistant recurrent or metastatic squamous cell carcinoma of head and neck: results of a Phase II study. Ann. Oncol. 21(Suppl.), Abstract 1035 (2010
44. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; Eastern Cooperative Oncology Group. Phase Iii randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 23, 8646-8654 (2005
45. Hitt R, Irigoyen A, Cortes-Funes H et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann. Oncol. 23, 1016-1022 (2012
46. Vermorken JB, Trigo J, Hitt R et al. Open-label, uncontrolled, multicenter Phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 25, 2171-2177 (2007).
47. Baselga J, Trigo JM, Bourhis J et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23, 5568-5577 (2005
48. Herbst RS, Arquette M, Shin DM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23, 5578-5587 (2005
49. Knoedler M, Gauler TC, Gruenwald V et al. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie. Oncology 84, 284-289 (2013
50. Péron J, Ceruse P, Lavergne E et al. Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. Anticancer Drugs 23, 996-1001 (2012
51. Muir CS, Waterhouse J, Mark T et al. Cancer Incidence in fIve Continents, vol.V. IARC Scientific Publication No. 88. International Agency for Research on Cancer (IARC), Lyon, France (1987
52. Parkin DM, Whelan SL, Ferlay J et al. Cancer Incidence in Five Continents, vol. VIii.IARC Scientific Publication No. 155. International Agency for Research on Cancer (IARC), Lyon, France (2002
53. Niedobitek G, Young LS, Sam CK, Brooks L, Prasad U, Rickinson AB. Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. Am. J. Pathol. 140, 879-887 (1992
54. Thompson L. Update on nasopharyngeal carcinoma. Head Neck Pathol. 1, 81-86 (2007
55. Lo YM, Chan AT, Chan LY et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 60, 6878-6881 (2000
56. Hou X, Zhang L, Zhao C et al. Prognostic impact of Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma. Chinese J. Cancer 25, 785-792 (2006
57. China Working Committee on Clinical Staging of Nasopharyngeal Cancer. Revision report on 1992 NPC staging. Chin. J. Radiat. Oncol. 18, 2-6 (2009
58. Hui EP, Ma BB, Leung SF et al. Randomized Phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvantdocetaxel and cisplatin in advanced nasopharyngeal carcinoma. J. Clin. Oncol. 27, 242-249 (2009
59. Wolden SL, Chen WC, Pfister DG et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int. J. Radiat. Oncol. Biol. Phys. 64, 57-62 (2006
60. Lin S, Pan J, Han L et al. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Int. J. Radiat. Oncol. Biol. Phys. 75, 1071-1078 (2009
61. Ma BB, Poon TC, To KF et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HEB2 receptor protein expression in undifferentiated nasopharyngeal carcinoma-A prospective study. Head Neck 25, 864-872 (2003
62. Fu J, Zhao B, Hu X et al. Clinical pathological significance of the expression of epidermal growth factor receptor in nasopharyngeal carcinoma. Chinese Journal of Otorhinolaryngology-Skull Base Surgery 10, 271-273 (2004
63. Chua DT, Nicholls JM, Sham JS, Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59, 11-20 (2004
64. Leong JL, Loh KS, Putti TC, Goh BC, Tan LK. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 114, 153-157 (2004
65. Zhu XF, Liu ZC, Xie BF et al. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett. 169, 27-32 (2001
66. Sung FL, Poon TC, Hui EP et al. Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells. In Vivo 19, 237-245 (2005
67. Huang SM, Bock JM, Harari RM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamouscell carcinomas of the head and neck. Cancer Res. 59, 1935-1940 (1999
68. Lu TX, Zhao C, Chen CY et al. An open multicenter clinical study on cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in nasopharyngeal carcinoma (NPC): preliminary report. Presented at: 46th ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2010 (Abstracy 42212
69. Ma BB, Kam MK, Leung SF et al. A Phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann. Oncol. 23, 1287-1292 (2012
70. Argiris AE, Gibson MK, Heron DE et al. Phase II trial of neoadjuvantdocetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (X), P, and E in locally advanced head and neck cancer (HNC). J. Clin. Oncol. 26(Suppl.), Abstract 6002 (2008
71. Mesia R, Vazquez S, Grau JJ et al. A single-arm Phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (TPF) as induction chemotherapy (IC) in patients (pts) with unresectable SCCHN. J. Clin. Oncol. 27(15 Suppl.), Abstract 6015 (2009
72. Kies MS, Holsinger FC, Lee JJ et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a Phase II prospective trial. J. Clin. Oncol. 28, 8-14 (2010
73. Chan AT, Hsu MM, Goh BC et al. Multicenter, Phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J. Clin. Oncol. 23, 3568-3576 (2005
74. Xu T, Hu C, Ying H et al. Cetuximab plus other methods in the treatment of patients with head and neck squamous cell carcinomas (HNSCC). China Oncology 18, 230-233 (2008
75. Bhayani MK, Weber RS. Multidisciplinary evaluation and treatment planning in head and neck cancer. In: Multidisciplinary Approach to Head and Neck Neoplasms. Har-el G, Day T, Nathan C, Nguyen SA (Eds). Thieme Medical Publishers, NY, USA (2013
76. Friedland PL, Bozic B, DewarJ,Kuan R, Meyer C, Phillips M. Impact of multidisciplinary team management in head and neck cancer patients. Br. J. Cancer 104, 1246-1248 (2011
77. Bradley PJ. Multidisciplinary clinical approach to the management of head and neck cancer. Eur. Arch. Otorhinolaryngol. 269, 2451-2454 (2012).